Lisa Harding
Psychiatry · Milford, CTNPI 1629427778
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $409,683 of the $607,565 with a category attached, or 67.4%. Johnson & Johnson accounts for 87.0% of it on its own, with 8 other manufacturers making up the rest. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 654 payments — averaging $929.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$529K
- Janssen Scientific Affairs, LLC$55K
- AbbVie$12K
- Eli Lilly$10K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- Axsome Therapeutics, Inc.$545
- plus $143 from 3 others
What the payments were for
- Consulting fees$92,50215%
- Speaking & faculty fees$409,68367%
- Travel & lodging$93,54415%
- Food & beverage$11,8362%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 596 | $528,874 |
| Janssen Scientific Affairs, LLC | 17 | $54,679 |
| AbbVie | 25 | $12,408 |
| Eli Lilly | 4 | $9,672 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $1,244 |
| Axsome Therapeutics, Inc. | 4 | $545 |
| Sage Therapeutics, LLC | 1 | $62 |
| Acadia Pharmaceuticals Inc | 1 | $53 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$576,881
- INVEGA SUSTENNA$7,814
- Auvelity$545
- INVEGA TRINZA$228
- INVEGA$228
How this compares
$607,565 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 63 | $72,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $528,874 | $72,27163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Milford
- Theddeus IheanachoMilford$74K
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
- David MatuskeyFarmington$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.